{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Avrobio, Inc.
Is Avrobio, Inc. technically bullish or bearish?
As of June 11, 2025, the market trend has shifted to mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite mixed signals from the MACD and Dow Theory.
Who are in the management team of Avrobio, Inc.?
As of March 2022, the management team of Avrobio, Inc. includes Dr. Bruce Booth (Independent Chairman), Mr. Geoff MacKay (President and CEO), and several independent directors: Dr. Gail Farfel, Mr. Ian Clark, Mr. Phillip Donenberg, Dr. Annalisa Jenkins, and Dr. Christopher Paige. This team provides leadership and strategic direction for the company.
What does Avrobio, Inc. do?
Avrobio, Inc. is a clinical-stage gene therapy company developing ex vivo lentiviral-based therapies for rare diseases, with a market cap of $378.25 million and a recent net profit of -$16 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.
How big is Avrobio, Inc.?
As of Jun 18, Avrobio, Inc. has a market capitalization of 378.25 million, with net sales of 0.00 million and a net profit of -58.67 million over the latest four quarters. As of Dec'24, shareholder's funds were 140.78 million and total assets were 152.91 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
